A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

← catalyst calendar

NCT05221840 · readout in 42 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

1,051actual

Sites

202

Countries

Australia, Brazil, Canada +17

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-02-07

actual

When the study began enrolling

Primary completion

2026-09-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-07-02

estimated

The whole study's end, after follow-up

First posted

2022-02-03

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Non-Small Cell Lung Cancer

Interventions

Drug: Durvalumab
Drug: Oleclumab
Drug: Monalizumab
Other: Placebo

Primary outcome

what the primary-completion date above is the date OF

Progression Free Surival (PFS)

measured Up to 5 years after first patient randomized.

Publications

PMID 39023287 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed